Chandraditya Chakraborty, Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Uterine Cervical Neoplasms | 8 | 2018 | 2020 | 1.180 |
Why?
|
| Cervix Uteri | 2 | 2017 | 590 | 0.890 |
Why?
|
| Gene Expression Regulation, Neoplastic | 7 | 2021 | 8428 | 0.590 |
Why?
|
| Von Hippel-Lindau Tumor Suppressor Protein | 1 | 2018 | 290 | 0.570 |
Why?
|
| Genes, p16 | 1 | 2016 | 157 | 0.540 |
Why?
|
| Retinoblastoma Binding Proteins | 1 | 2016 | 97 | 0.540 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2018 | 627 | 0.480 |
Why?
|
| beta Catenin | 1 | 2017 | 1059 | 0.420 |
Why?
|
| DNA Methylation | 5 | 2018 | 4286 | 0.350 |
Why?
|
| Human papillomavirus 16 | 4 | 2015 | 262 | 0.330 |
Why?
|
| Neoplasm Proteins | 2 | 2020 | 3703 | 0.330 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2018 | 2915 | 0.310 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2018 | 3508 | 0.290 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2016 | 1861 | 0.290 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2016 | 2849 | 0.270 |
Why?
|
| Uterine Cervical Dysplasia | 3 | 2015 | 387 | 0.270 |
Why?
|
| Receptors, Cell Surface | 1 | 2014 | 2866 | 0.250 |
Why?
|
| Promoter Regions, Genetic | 5 | 2018 | 5867 | 0.210 |
Why?
|
| HeLa Cells | 2 | 2018 | 3128 | 0.200 |
Why?
|
| 14-3-3 Proteins | 1 | 2020 | 214 | 0.170 |
Why?
|
| Multiple Myeloma | 3 | 2024 | 5181 | 0.170 |
Why?
|
| Ubiquitin-Conjugating Enzymes | 1 | 2019 | 195 | 0.170 |
Why?
|
| Papillomavirus Infections | 3 | 2015 | 1587 | 0.150 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2023 | 5172 | 0.140 |
Why?
|
| Evolution, Molecular | 2 | 2023 | 1940 | 0.140 |
Why?
|
| Prognosis | 2 | 2021 | 29063 | 0.130 |
Why?
|
| Genomics | 3 | 2023 | 5720 | 0.130 |
Why?
|
| Oligopeptides | 1 | 2020 | 1189 | 0.120 |
Why?
|
| Ubiquitin | 1 | 2019 | 852 | 0.120 |
Why?
|
| Adenocarcinoma | 2 | 2023 | 6364 | 0.120 |
Why?
|
| Genomic Instability | 3 | 2024 | 695 | 0.120 |
Why?
|
| Oncogene Proteins, Viral | 2 | 2015 | 362 | 0.120 |
Why?
|
| Neoplasm Staging | 3 | 2018 | 11031 | 0.110 |
Why?
|
| Alphapapillomavirus | 1 | 2016 | 221 | 0.110 |
Why?
|
| Cell Transformation, Viral | 1 | 2015 | 565 | 0.110 |
Why?
|
| Gene Expression Regulation, Viral | 2 | 2015 | 442 | 0.110 |
Why?
|
| Epithelium | 1 | 2017 | 1679 | 0.110 |
Why?
|
| DNA Copy Number Variations | 2 | 2018 | 1941 | 0.110 |
Why?
|
| Papillomavirus E7 Proteins | 1 | 2011 | 123 | 0.100 |
Why?
|
| Esophageal Neoplasms | 1 | 2021 | 1583 | 0.100 |
Why?
|
| Mutation | 3 | 2021 | 29786 | 0.090 |
Why?
|
| Interleukin-1beta | 1 | 2015 | 972 | 0.090 |
Why?
|
| Cell Line, Tumor | 4 | 2023 | 16689 | 0.080 |
Why?
|
| DNA, Viral | 1 | 2015 | 2225 | 0.080 |
Why?
|
| Gene Regulatory Networks | 1 | 2016 | 1708 | 0.080 |
Why?
|
| Survival Rate | 2 | 2021 | 12788 | 0.080 |
Why?
|
| Phosphorylation | 1 | 2016 | 8436 | 0.060 |
Why?
|
| Repressor Proteins | 2 | 2015 | 3023 | 0.060 |
Why?
|
| Epigenesis, Genetic | 2 | 2015 | 3647 | 0.060 |
Why?
|
| Tumor Cells, Cultured | 2 | 2021 | 6314 | 0.050 |
Why?
|
| Female | 10 | 2021 | 380194 | 0.050 |
Why?
|
| Melphalan | 1 | 2024 | 431 | 0.050 |
Why?
|
| Chromosomal Instability | 1 | 2023 | 184 | 0.050 |
Why?
|
| Deoxyribonucleases | 1 | 2023 | 214 | 0.050 |
Why?
|
| Antineoplastic Agents | 1 | 2024 | 13695 | 0.050 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2016 | 4034 | 0.050 |
Why?
|
| Humans | 13 | 2024 | 744343 | 0.040 |
Why?
|
| India | 2 | 2015 | 2197 | 0.040 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2023 | 2649 | 0.040 |
Why?
|
| Mice, SCID | 1 | 2021 | 2716 | 0.030 |
Why?
|
| Cell Cycle | 1 | 2023 | 2967 | 0.030 |
Why?
|
| Genes, Neoplasm | 1 | 2016 | 376 | 0.030 |
Why?
|
| Chromosomes, Human | 1 | 2016 | 457 | 0.030 |
Why?
|
| Human papillomavirus 18 | 1 | 2015 | 128 | 0.030 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2021 | 3557 | 0.030 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2023 | 2942 | 0.030 |
Why?
|
| Virus Integration | 1 | 2015 | 299 | 0.030 |
Why?
|
| Mice, Inbred BALB C | 1 | 2021 | 6386 | 0.030 |
Why?
|
| Asymptomatic Diseases | 1 | 2015 | 551 | 0.030 |
Why?
|
| Pyrimidines | 1 | 2024 | 2942 | 0.030 |
Why?
|
| Enhancer Elements, Genetic | 1 | 2015 | 1341 | 0.020 |
Why?
|
| Open Reading Frames | 1 | 2011 | 810 | 0.020 |
Why?
|
| Aged | 3 | 2015 | 163280 | 0.020 |
Why?
|
| Disease Progression | 2 | 2015 | 13284 | 0.020 |
Why?
|
| Middle Aged | 3 | 2015 | 213383 | 0.020 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2016 | 15519 | 0.020 |
Why?
|
| Host-Pathogen Interactions | 1 | 2015 | 1477 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2021 | 10481 | 0.020 |
Why?
|
| Mice | 2 | 2023 | 81183 | 0.020 |
Why?
|
| Apoptosis | 1 | 2021 | 9727 | 0.020 |
Why?
|
| Cell Line | 1 | 2015 | 15997 | 0.010 |
Why?
|
| Animals | 2 | 2023 | 168757 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2016 | 19905 | 0.010 |
Why?
|
| Prevalence | 1 | 2015 | 15226 | 0.010 |
Why?
|
| DNA-Binding Proteins | 1 | 2015 | 9648 | 0.010 |
Why?
|
| Inflammation | 1 | 2015 | 10638 | 0.010 |
Why?
|
| Male | 2 | 2023 | 350118 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2015 | 17446 | 0.010 |
Why?
|
| Adult | 2 | 2015 | 214055 | 0.010 |
Why?
|